CY1124982T1 - Εμβολιο mycoplasma hyopneumoniae - Google Patents

Εμβολιο mycoplasma hyopneumoniae

Info

Publication number
CY1124982T1
CY1124982T1 CY20221100121T CY221100121T CY1124982T1 CY 1124982 T1 CY1124982 T1 CY 1124982T1 CY 20221100121 T CY20221100121 T CY 20221100121T CY 221100121 T CY221100121 T CY 221100121T CY 1124982 T1 CY1124982 T1 CY 1124982T1
Authority
CY
Cyprus
Prior art keywords
mycoplasma hyopneumoniae
hyopneumoniae vaccine
hyo
soluble portion
preparation
Prior art date
Application number
CY20221100121T
Other languages
Greek (el)
English (en)
Inventor
Jeffrey E. Galvin
Gregory P. Nitzel
John Keith GARRETT
James R. II KULAWIK
Tracy L. RICKER
Megan Marie SMUTZER
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48087777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124982(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CY1124982T1 publication Critical patent/CY1124982T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation
    • C12N2750/10063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/10011—Arteriviridae
    • C12N2770/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CY20221100121T 2012-04-04 2022-02-11 Εμβολιο mycoplasma hyopneumoniae CY1124982T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620165P 2012-04-04 2012-04-04
PCT/US2013/035083 WO2013152081A1 (en) 2012-04-04 2013-04-03 Mycoplasma hyopneumoniae vaccine

Publications (1)

Publication Number Publication Date
CY1124982T1 true CY1124982T1 (el) 2023-01-05

Family

ID=48087777

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100121T CY1124982T1 (el) 2012-04-04 2022-02-11 Εμβολιο mycoplasma hyopneumoniae

Country Status (31)

Country Link
US (5) US9120859B2 (enExample)
EP (2) EP2833908B1 (enExample)
JP (1) JP6271502B2 (enExample)
KR (1) KR101747507B1 (enExample)
CN (1) CN104271154B (enExample)
AR (1) AR090611A1 (enExample)
AU (1) AU2013243535C1 (enExample)
BR (1) BR112014024533B1 (enExample)
CA (1) CA2869603C (enExample)
CL (1) CL2014002674A1 (enExample)
CO (1) CO7160026A2 (enExample)
CR (1) CR20140436A (enExample)
CY (1) CY1124982T1 (enExample)
DK (1) DK2833908T3 (enExample)
ES (1) ES2905302T3 (enExample)
GT (1) GT201400210A (enExample)
HR (2) HRP20140957A2 (enExample)
HU (1) HUE058321T2 (enExample)
LT (1) LT2833908T (enExample)
MX (2) MX336504B (enExample)
MY (1) MY166792A (enExample)
NI (1) NI201400117A (enExample)
PH (1) PH12014502250A1 (enExample)
PL (1) PL2833908T3 (enExample)
PT (1) PT2833908T (enExample)
RS (1) RS62881B1 (enExample)
RU (1) RU2644254C2 (enExample)
SI (1) SI2833908T1 (enExample)
TW (1) TWI602575B (enExample)
UA (1) UA114502C2 (enExample)
WO (1) WO2013152081A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
US9878027B2 (en) 2012-12-28 2018-01-30 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition comprising mycoplasma antigens
UA121193C2 (uk) 2012-12-28 2020-04-27 Бьорінгер Інгельхайм Ветмедіка Гмбх Спосіб одержання імуногенної композиції проти мікоплазми
DK2994162T3 (en) 2013-05-08 2021-06-21 Pharmgate Biologics Inc Vaccine for pcv2 og mycoplasma
CN104248759B (zh) * 2013-11-19 2017-05-10 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
MX382924B (es) * 2013-11-21 2025-03-13 Agricultural Tech Res Inst Composición para prevenir infección por mycoplasma spp.
EP3151838A4 (en) * 2014-06-04 2017-11-29 Izard, Ryan Methods and compositions for orally dosing postnatal swine
BR102014014727B1 (pt) * 2014-06-16 2018-04-03 Ouro Fino Saúde Animal Ltda COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, GENE SINTÉTICO CODIFICANTE DO COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae, COMPOSIÇÃO ANTIGÊNICA, PROCESSO DE OBTENÇÃO DE UM COMPLEXO DE POLIPROTEÍNAS IMUNOGÊNICAS DE M. hyopneumoniae
CN104324370B (zh) * 2014-09-30 2019-12-20 普莱柯生物工程股份有限公司 疫苗组合物及其制备方法和应用
KR20180094116A (ko) * 2016-01-07 2018-08-22 유니버시테이트 젠트 브라키스피라 하이오디센테리애의 백신 균주
JP2019509302A (ja) * 2016-03-23 2019-04-04 インターベット インターナショナル ベー． フェー． アルブミンを含むｐｃｖ２及びｐｒｒｓウイルス感染症に対する混合ワクチン
CN106497850B (zh) * 2016-12-20 2019-10-29 天津瑞普生物技术股份有限公司 一种纯化猪肺炎支原体的方法
RU2761453C2 (ru) 2016-12-23 2021-12-08 Интервет Интернэшнл Б.В. Комбинированная вакцина для свиней
JP7510874B2 (ja) * 2017-12-22 2024-07-04 ヒプラ シエンティフィック エセ．エレ．ウ． マイコプラズマ及びブタサーコウイルスに対する皮内混合ワクチン
CA3141075A1 (en) * 2019-06-10 2020-12-17 Arvind Kumar Mycoplasma media formulations
WO2021018806A1 (en) * 2019-07-26 2021-02-04 Ceva Sante Animale Igg-depleted porcine serum and the uses thereof
AU2021311726A1 (en) * 2020-07-24 2023-02-09 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine
KR20220168097A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168100A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168101A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168102A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168098A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
KR20220168099A (ko) 2021-06-15 2022-12-22 엘지전자 주식회사 조리기기
CN114134098A (zh) * 2021-12-15 2022-03-04 成都史纪生物制药有限公司 一种猪肺炎支原体的灭活方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4606918A (en) 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4681870A (en) * 1985-01-11 1987-07-21 Imre Corporation Protein A-silica immunoadsorbent and process for its production
JPH0832637B2 (ja) 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
EP0263840A1 (de) 1986-03-13 1988-04-20 ZF FRIEDRICHSHAFEN Aktiengesellschaft Einrichtung zum bestrahlen von flüssigkeiten mit radioaktiven strahlen
US5084269A (en) 1986-11-06 1992-01-28 Kullenberg Fred W Adjuvant for dose treatment with antigens
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5252328A (en) * 1987-03-26 1993-10-12 Martin Marietta Energy Systems, Inc. Mycoplasma hyopneumoniae antigen and uses therefor
EP0283840A3 (en) 1987-03-26 1989-08-09 Ml Technology Ventures, L.P. Mycoplasma hyopneumoniae antigen and uses therefor
IE63692B1 (en) 1987-11-03 1995-05-31 Syntex Inc Vaccine adjuvant
US4985243A (en) 1988-01-20 1991-01-15 Ml Technology Ventures, L.P. Composition and method for protecting against diseases caused by microorganisms
US5240706A (en) 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
ZA906806B (en) 1989-08-31 1991-06-26 Ici Australia Operations Plants
US6113916A (en) 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
AU657907B2 (en) 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
US5695769A (en) 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
CA2103460C (en) 1991-06-06 2000-09-26 Gert Wensvoort Causative agent of the mystery swine disease, vaccine compositions and diagnostic kits
CA2116348C (en) 1991-08-26 2001-07-03 James E. Collins Sirs vaccine and diagnosis method
DK0610250T4 (da) 1991-10-14 2009-03-02 Intervet Int Bv Vaccine med porcint reproduktivt respiratorisk syndrom (PRRS) og diagnose heraf
DK0669971T3 (da) 1991-11-15 2003-04-22 Pfizer Fremgangsmåde til fremstilling af Gram-negative bakterielle vacciner
FR2686097B1 (fr) 1992-01-14 1994-12-30 Rhone Merieux Preparation d'antigenes et de vaccins de virus de la mystery disease, antigenes et vaccins obtenus pour la prevention de cette maladie.
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
US6773908B1 (en) 1992-10-30 2004-08-10 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
US6251397B1 (en) 1992-10-30 2001-06-26 Iowa State University Research Foundation, Inc. Proteins encoded by polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus and immunogenic compositions containing the same
US5695766A (en) 1992-10-30 1997-12-09 Iowa State University Research Foundation Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome
US6380376B1 (en) 1992-10-30 2002-04-30 Iowa State University Research Foundation Proteins encoded by polynucleic acids of porcine reproductive and respiratory syndrome virus (PRRSV)
ES2074950B1 (es) 1993-09-17 1996-03-16 Iberica Cyanamid Vacuna para la prevencion de la enfermedad reproductiva y respiratoria de la cerda.
SI0968722T1 (sl) 1994-05-10 2007-10-31 Wyeth Corp Izboljĺ ano, modificirano ĺ˝ivo cepivo proti brsv
BE1008978A5 (fr) 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5788962A (en) 1995-01-17 1998-08-04 The Curators Of The University Of Missouri DNA sequences coding for mycoplasma hyopneumoniae surface antigens, corresponding proteins and use in vaccines and diagnostic procedures
AUPN178995A0 (en) 1995-03-16 1995-04-13 University Of Melbourne, The Antigen composition
US5820869A (en) 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
GB9622159D0 (en) 1996-10-24 1996-12-18 Solvay Sociutu Anonyme Polyanionic polymers as adjuvants for mucosal immunization
EP0839912A1 (en) 1996-10-30 1998-05-06 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof
EP0948625B1 (en) 1996-12-20 2011-01-26 The Board Of Regents, The University Of Texas System Uspa1 and uspa2 antigens of moraxella catarrhalis
KR20010032493A (ko) 1997-11-26 2001-04-25 아이오와 스테이트 유니버시티 리서치 파운데이션, 인코퍼레이티드 재조합 미코플라스마 히오뉴모니아(Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ) 백신
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
NZ501264A (en) 1998-12-22 2001-09-28 Pfizer Prod Inc Polynucleotide DNA sequence encoding an infectious RNA molecule encoding a North American PRRS
US6632439B2 (en) 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
KR20040030785A (ko) * 2001-07-02 2004-04-09 화이자 프로덕츠 인크. 마이코플라즈마 하이오뉴모니애로의 1회 투여량 예방접종
WO2003004051A2 (en) * 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7419806B2 (en) 2002-06-28 2008-09-02 Iowa State University Research Foundation, Inc. Immunogenic Mycoplasma hyopneumoniae polypeptides
JP2006528647A (ja) * 2003-07-24 2006-12-21 メリアル リミテッド 新規ワクチン製剤
US8449989B2 (en) 2003-10-17 2013-05-28 Lg Chem, Ltd. Organic compound and organic light emitting device using the same
ATE462445T1 (de) 2005-01-13 2010-04-15 Boehringer Ingelheim Vetmed Prrs-impfstoffe
DK1926496T3 (da) * 2005-09-09 2013-09-30 Intervet Int Bv PCV-2-vaccine
EP1792996A1 (en) 2005-12-01 2007-06-06 Consejo Superior de Investigaciones Cientificas Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
EP3320919B1 (en) 2005-12-29 2020-05-27 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
CA2646574C (en) 2006-04-10 2012-08-21 Intervet International B.V. Vaccine against mycoplasma and prrsv
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
ME01000B (me) * 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
CA2712006A1 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
EP2356132A2 (en) 2008-10-16 2011-08-17 Pfizer Inc. Torque teno virus (ttv) isolates and compositions
EP2569007B1 (en) 2010-05-11 2015-10-14 Intervet International B.V. Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
CA2808285C (en) * 2010-08-27 2016-09-06 Intervet International B.V. Potency test for vaccine formulations
US8546149B2 (en) 2010-08-27 2013-10-01 Intervet Inc. Potency test for vaccine formulations
UA108902C2 (uk) 2010-11-10 2015-06-25 Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування
WO2013131565A1 (en) 2012-03-07 2013-09-12 Ceva Sante Animale Novel veterinary vaccine
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
US9120859B2 (en) * 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN104302316A (zh) * 2012-05-17 2015-01-21 佐蒂斯有限责任公司 在断奶之前对抗猪繁殖与呼吸综合征(prrs)病毒的有效疫苗接种

Also Published As

Publication number Publication date
US10668139B2 (en) 2020-06-02
WO2013152081A1 (en) 2013-10-10
ES2905302T3 (es) 2022-04-07
MY166792A (en) 2018-07-23
MX354756B (es) 2018-03-20
HRP20140957A2 (hr) 2015-02-27
CN104271154B (zh) 2018-09-04
AU2013243535A1 (en) 2014-10-09
RS62881B1 (sr) 2022-03-31
US9650600B2 (en) 2017-05-16
RU2644254C2 (ru) 2018-02-08
BR112014024533B1 (pt) 2021-06-01
MX2014012014A (es) 2014-11-10
PH12014502250B1 (en) 2014-12-15
CA2869603A1 (en) 2013-10-10
HRP20220175T1 (hr) 2022-04-29
LT2833908T (lt) 2022-02-25
US9120859B2 (en) 2015-09-01
AR090611A1 (es) 2014-11-26
BR112014024533A2 (pt) 2017-08-08
PL2833908T3 (pl) 2022-03-21
JP6271502B2 (ja) 2018-01-31
DK2833908T3 (da) 2022-02-07
KR20150003257A (ko) 2015-01-08
CA2869603C (en) 2018-06-12
CO7160026A2 (es) 2015-01-15
HUE058321T2 (hu) 2022-07-28
US20190134176A1 (en) 2019-05-09
KR101747507B1 (ko) 2017-06-14
TW201345550A (zh) 2013-11-16
AU2013243535C1 (en) 2018-03-01
MX336504B (es) 2016-01-21
RU2014140107A (ru) 2016-05-27
EP2833908B1 (en) 2022-01-05
TWI602575B (zh) 2017-10-21
US11141472B2 (en) 2021-10-12
NI201400117A (es) 2015-03-05
PH12014502250A1 (en) 2014-12-15
JP2015512448A (ja) 2015-04-27
GT201400210A (es) 2015-06-02
US20130266601A1 (en) 2013-10-10
HK1207284A1 (en) 2016-01-29
CL2014002674A1 (es) 2014-12-12
CN104271154A (zh) 2015-01-07
US10206991B2 (en) 2019-02-19
AU2013243535B2 (en) 2017-10-19
CR20140436A (es) 2014-11-12
US20150284677A1 (en) 2015-10-08
PT2833908T (pt) 2022-02-17
US20200330577A1 (en) 2020-10-22
US20170209560A1 (en) 2017-07-27
UA114502C2 (uk) 2017-06-26
SI2833908T1 (sl) 2022-04-29
EP4039271A1 (en) 2022-08-10
EP2833908A1 (en) 2015-02-11

Similar Documents

Publication Publication Date Title
CY1124982T1 (el) Εμβολιο mycoplasma hyopneumoniae
CY1121998T1 (el) Συνδυασμενο εμβολιο pcv/mycoplasma hyopneumoniae
CY1121578T1 (el) Εμβολιο συνδυασμου pcv/mycoplasma hyopneumoniae/prrs
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
CY1122699T1 (el) Συνθεσεις μεσοπορωδους πυριτιας για διαμορφωση ανοσοαποκρισεων
CY1124252T1 (el) Anti-lag3 αντισωματα και θραυσματα συνδεσης αντιγονου
CY1122953T1 (el) Ενα καινοτομο συμπλοκο που περιλαμβανει ενα κυτταροδιεισδυτικο πεπτιδιο, ενα φορτιο και εναν tlr πεπτιδικο αγωνιστη για την αντιμετωπιση του ορθοκολικου καρκινου
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1121870T1 (el) Anti-egfrviii αντισωματα και χρησεις αυτων
MX2016003744A (es) Anticuerpos tem8 y su uso.
CY1121389T1 (el) Αντισωματα που δεσμευονται ειδικα με την α-τοξινη toy staphylococcus aureus και μεθοδοι χρησης
CY1119069T1 (el) Σκευασματα αντισωματων υψηλης συγκεντρωσης δια παραπομπη προς συναφεις εφαρμογες
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
EA201790239A1 (ru) Молекула-носитель для антигенов
EA201591801A1 (ru) Лекарственные конъюгаты антител
MX2016013218A (es) Molecula de unión al antígeno trifuncional.
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
EA201690857A1 (ru) Конъюгатные вакцины на основе сальмонеллы
CY1116706T1 (el) Εμβολια προϊοντος συζευξης αντιγονου πολυσακχαριδιου γλυκολιπιδιου
WO2012103444A3 (en) Immunogenic compositions and reagents for preparing
TH173041A (th) วัคซีนรวมของ pvc/ไมโครพลาสมา ไฮโอนิวโมเนีย/prrs
TH159844A (th) วัคซีนของวัคซีนของไมโคพลาสมา ไฮโอพนิวโมนิเอ (mycoplasma hyopneumoniae)
TH159867A (th) วัคซีนการรวมของ pcv/ ไมโคพลาสมา ไฮโอพนิวโมนิเอ (mycoplasma hyopneumoniae)